JDRF, which works to find a cure for juvenile diabetes patients (type 1), and the pharmaceutical company Sanofi will invest up to 4.6 million dollars in order to accelerate the innovative development of insulin of the GRI type
JDRF, which works to find a cure for juvenile diabetes patients (type 1), and the pharmaceutical company Sanofi will invest up to 4.6 million dollars in order to accelerate the innovative development of insulin of the GRI type (Glucose Responsive Insulin). . JDRF's experienced scientific team, which is at the forefront of research to find a cure for juvenile diabetes, is the one who selected the researchers who will receive the funding, and will subsequently provide guidance throughout the study. Also, Sanofi's medical research team will provide scientific expertise for research and development, in order to create a successful transition of the research projects to clinical development intended for humans.
Type 1 diabetes is a chronic autoimmune disease that attacks the body and destroys its ability to produce insulin independently. As of today, there is no clinic for type 1 diabetes, so patients with the disease remain dependent on the need to inject insulin throughout their lives. The importance of maintaining the balance of sugar values is critical; An imbalance means additional medical complications that may endanger the diabetic's life, and worsen his condition to the point of blindness, kidney failure, limb amputation and even stroke. A type 1 diabetic checks the sugar levels in his body about 12 times a day using a needle, and injects insulin between 3-6 times a day into his body.
The new development of GRI type insulin may provide an answer to the shortcomings and challenges that exist today in insulin treatment. The four researchers aim to produce therapeutic insulin that will more safely prevent dangerous increases and decreases in insulin levels. The ambition is that the future treatment will be able to maintain the blood sugar levels in the long term and in a more reliable way, which will lead to a reduction in the burden of managing the disease on the type 1 diabetic, the frequency of taking insulin will be reduced.
The Association for Juvenile Diabetes (type 1) regretted its banner to work for the promotion of the interests and rights of the patients before governmental, public and private bodies. The association is a branch of the global foundation JDRF, which is engaged in promoting research on type 1 diabetes. The association encourages and supports research in Israel, and has invested over NIS 90 million in research, with the determination to find a cure for diabetes and promote the improvement of the quality of life of patients with the disease. Among her achievements: the introduction of advanced insulin pumps and the continuous glucose meter device into the health basket, the establishment of juvenile diabetes clinics for children, the anchoring of assistance arrangements in legislation for diabetic children aged 3-9 in schools, and more.
